Abstract 848P
Background
Little is known about the unique features prognosis of young patients with epithelial ovarian cancer (EOC). We aimed to describe clinic-pathological features and survival in a population of patients aged <45 years treated in a single institution for EOC over a 30-year period.
Methods
We recovered the medical files of all the patients <45 years of age treated between 1990 and 2020 for EOC at the Gustave Roussy Cancer Center. Progression-free and overall survival distributions (PFS and OS), median follow-up, and the 95% CI were calculated using the reverse Kaplan–Meier method.
Results
Overall, 140 pts were included in the analysis. Concerning histology, only 26% (36/140) were HGSOC, the next most frequent histology was mucinous with 23.6% (33/140) pts. Other histologies included: endometrioid (16%), low grade serous (15%), clear cell (8.5%), Brenner tumour (3.5%), undifferentiated (3%), anaplastic (2%), mixed (9%);2% histology was not available (NA). Stage at diagnosis was I, II, III and IV in 49 (35%), 3 (2%), 74 (53%), 11 (8%) pts respectively; NA in 2.1%. Median age was 29.5 (13-45) years (yrs), 19 (13.5%) pts had a BRCA1 or 2 mutation. Among HGSOC the rate was 50% (19/36). In terms of treatment, most achieved complete debulking surgery (81%, 114/140). Among 85 pts with stage III-IV, 36 (43%) had inextirpable disease at diagnosis. With regards to survival and a median follow-up of 8.7 years (95%IC 0.1-34.4), median PFS was 3.9 (95%IC 2.9-6.2) yrs, median OS was not reached (95%IC 12.2-NR) in the whole population. In stage I-II, median PFS and OS was 22.7 (95% CI 20.1-26) and 23.1 yrs (16.5-29) respectively; In stage III-IV median PFS and OS was 27.5 ( 95% CI 17,4-37,6) and 97.6 months (95% CI 27-168,3) respectively. In HGSOC pts, 27 (75%) pts relapsed, and 16 (44%) were dead from disease. PFS and OS was 27.5 (95% CI 22.4-32.6) and 97.6 months (95 % CI 57.4-137.9) respectively.
Conclusions
Distribution of histology differs in younger EOC, with only 25% of HGSOC compared to 75% among older women, but is enriched for rare histologies. Among young pts with HGSOC, the rate of BRCA mutation was 50%. Good prognosis is driven by low stage in this cohort. Further molecular characterisation is on-going to explore the relation of age with established risk factor in pts treated for OC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Colomba-Blameble: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Advisory/Consultancy: Sanofi; Honoraria (institution), Advisory/Consultancy: GSK. P. Pautier: Advisory/Consultancy, Travel/Accommodation/Expenses: Eoche; Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy: Tesaro; Advisory/Consultancy: Genentech; Advisory/Consultancy: Clovis; Research grant/Funding (institution): PharmaMar. A. Leary: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Clovis; Honoraria (institution), Advisory/Consultancy: PharmaMar; Honoraria (institution), Advisory/Consultancy: Tesaro; Advisory/Consultancy: Gammamabs; Advisory/Consultancy: Pfizer; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Seattle genetics; Research grant/Funding (institution): Inivata; Research grant/Funding (self), Research grant/Funding (institution): Merus; Research grant/Funding (institution): MSD. All other authors have declared no conflicts of interest.